OCYTOCIN
ActiveSummary
OCYTOCIN has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €139,289 and a net result of €16,953. Equity is shrinking by about 8.6% per year across the filed financial years. Its solvency ranks better than 46% of 39,152 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
23-07
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Back to profitnet €16,953
Net result €16,953 after 2 loss-making years.
30-07
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
24-07
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Weakest financial yearnet -€17,750
Net result drops to -€17,750, the lowest in the series; recovery starts the following year.
31-08
NBB filing
Annual accounts filed
financial year 2022 · micro format · 31 days late
2022
28-07
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
31-12
Financial
Highest result from 2020 to 2025net €163,209 ▲181%
Operating result €211,885, net result €163,209, both a record.
31-12
Financial
Equity above €200,000equity €226,215 ▲259%
A profit in every financial year since 2020 builds equity to €226,215.
29-07
NBB filing
Annual accounts filed
financial year 2020 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.